Abstract
The uniqueness of paclitaxel’s antimitotic action mechanism has fueled research toward its application in more effective and safer cancer treatments. However, the low water solubility, recrystallization, and side effects hinder the clinical success of classic paclitaxel chemotherapy. The aim of this study was to evaluate the in vivo efficacy and biodistribution of paclitaxel encapsulated in injectable amphiphilic cyclodextrin nanoparticles of different surface charges. It was found that paclitaxel-loaded amphiphilic cyclodextrin nanoparticles showed an antitumoral effect earlier than the drug solution. Moreover, the blank nanoparticles reduced the tumor growth with a similar trend to the paclitaxel solution. At 24 h, the nanoparticles had not accumulated in the heart and lungs according to the biodistribution assessed by in vivo imaging. Therefore, our results indicated that the amphiphilic cyclodextrin nanoparticles are potentially devoid of cardiac toxicity, which limits the clinical use and commercialization of certain polymeric nanoparticles. In conclusion, the amphiphilic cyclodextrin nanoparticles with different surface charge increased the efficiency of paclitaxel in vitro and in vivo. Cyclodextrin nanoparticles could be a good candidate vehicle for intravenous paclitaxel delivery.
Highlights
Paclitaxel (PCX) is an effective anticancer drug used in many types of cancer including breast, ovarian, lung, head, and neck cancers
Monodisperse PCX-loaded amphiphilic CD nanoparticles were reproducibly produced from 6OCaproβCD and PC βCDC6 (82 ± 2 nm), respectively
The antitumoral activities of two different CD derivatives, which were determined by our group to be safe carriers for cancer treatment in previous studies, were supported by in vivo studies
Summary
Paclitaxel (PCX) is an effective anticancer drug used in many types of cancer including breast, ovarian, lung, head, and neck cancers. The solubility of PCX in aqueous media is very low (
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have